Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 870 (109th)

PhRMA Act of 2005

referredUnited States· United States Congress· EN

Introduced

16 February 2005

Last action

14 March 2005 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Stark, Fortney Pete [D-CA-13], Rep. Berry, Marion [D-AR-1], Rep. Cummings, Elijah E. [D-MD-7], Rep. Israel, Steve [D-NY-3], Rep. McGovern, James P. [D-MA-2], Rep. Woolsey, Lynn C. [D-CA-6], Rep. Kucinich, Dennis J. [D-OH-10], Rep. Kildee, Dale E. [D-MI-5], Rep. McDermott, Jim [D-WA-7], Rep. Owens, Major R. [D-NY-11], Rep. Jackson Lee, Sheila [D-TX-18], Sen. Sanders, Bernard [I-VT], Rep. Hinchey, Maurice D. [D-NY-22], Rep. Solis, Hilda L. [D-CA-32]

Subjects

Healthcare

Source updated

15 August 2025

Healthcare

Summary

Pharmaceutical Research and Manufacturers Accountability Act of 2005 or the PhRMA Act of 2005 - Sets forth penalties for violations of acts prohibited under the Federal Food, Drug, and Cosmetic Act by an individual employed as the chief executive officer or as a member of the senior executive management group of the manufacturer of a drug, where the violation involves knowing concealment of evidence of a serious adverse drug experience. Requires the Secretary of Health and Human Services to require the chief executive officer of the manufacturer of a Food and Drug Administration (FDA)-approved drug to annually: (1) attest that the manufacturer has disclosed to the Secretary all evidence of any serious adverse drug experience related to the drug; and (2) describe the process by which the manufacturer ensures that such disclosure has occurred. Allows the Secretary to withdraw an approval for such a drug for failure to provide such an attestation. Prohibits a chief executive officer of a manufacturer of such a drug from failing to provide such an attestation. Requires the Secretary to direct a manufacturer or sponsor of a drug to complete any required postmarketing study of that drug by a specified deadline. Allows the Secretary to extend such a deadline. Sets forth penalties for failing to meet such a deadline.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 16 February 2005

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 16 February 2005

    Introduced

    Sponsor introductory remarks on measure. (CR E252)

    Source: IntroReferral

  3. 16 February 2005

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 16 February 2005

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 14 March 2005

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 16 February 2005

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 16 February 2005

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 16 February 2005

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.